Acute Kidney Injury — Part 5: Special Populations & Long-Term Outcomes
Sepsis-associated AKI, cardiac surgery-associated AKI, contrast-associated AKI, hepatorenal syndrome, rhabdomyolysis, tumor lysis syndrome, AKI in pregnancy, long-term outcomes, CKD progression, nephrology referral criteria, and quality metrics.
1. Sepsis-Associated AKI (SA-AKI)
1.1 Epidemiology
Sepsis is the most common cause of AKI in the ICU, accounting for approximately 40-50% of all ICU-associated AKI cases. Sepsis-associated AKI carries a higher mortality than either sepsis or AKI alone, with hospital mortality rates of 40-60%.1 2
1.2 Pathophysiology — Distinct from Classical Ischemic ATN
The pathophysiology of SA-AKI is fundamentally different from classical hypovolemic/ischemic ATN, and this distinction has important management implications:1 2
| Feature | Classical Ischemic ATN | Sepsis-Associated AKI |
|---|---|---|
| Renal blood flow | Decreased (global hypoperfusion) | Often normal or increased |
| Histopathology | Widespread tubular necrosis | Minimal or absent tubular necrosis; vacuolization; apoptosis (not necrosis); inflammatory cell infiltration |
| Mechanism | Ischemia-reperfusion injury to tubular cells | Microvascular dysfunction (heterogeneous perfusion); intrarenal shunting; mitochondrial dysfunction and “metabolic hibernation”; toll-like receptor (TLR) activation by DAMPs/PAMPs; tubular cell cycle arrest; efferent arteriolar vasoconstriction |
| GFR reduction | Due to reduced renal blood flow | Due to afferent arteriolar vasodilation with efferent arteriolar dilation (reduced filtration pressure); intrarenal shunting bypassing glomeruli |
| Response to volume expansion | May improve (restore perfusion) | Often does not improve and may worsen (fluid overload → renal venous congestion → further GFR decline) |
| Recovery | Variable; may take weeks | Often recovers rapidly with resolution of sepsis (consistent with functional rather than structural injury) |
1.3 Management Implications
| Principle | Rationale |
|---|---|
| Avoid aggressive fluid resuscitation after initial stabilization | Renal blood flow is often adequate; excessive fluids worsen venous congestion and interstitial edema; the kidney is an encapsulated organ vulnerable to increased interstitial pressure |
| Maintain adequate perfusion pressure (MAP ≥ 65 mmHg) | Vasopressors (norepinephrine) to maintain MAP are preferred over additional fluid boluses once initial resuscitation is complete |
| Remove nephrotoxins | Septic kidneys are more vulnerable to superimposed nephrotoxic injury |
| Avoid unnecessary RRT | SA-AKI often recovers rapidly with resolution of sepsis; the IDEAL-ICU trial showed that 38% of patients with septic shock and severe AKI recovered without RRT |
| Target source control | Treatment of the underlying infection is the most important intervention for SA-AKI recovery |
1.4 Biomarkers in SA-AKI
The cell-cycle arrest biomarkers (TIMP-2 and IGFBP7) have demonstrated particular utility in predicting SA-AKI, with the best performance in the early identification of patients who will progress from no-AKI or Stage 1 to Stage 2-3 AKI within 12-24 hours. This may allow early implementation of nephroprotective bundles (avoidance of nephrotoxins, optimization of hemodynamics, avoidance of fluid overload).3
2. Cardiac Surgery-Associated AKI (CSA-AKI)
2.1 Epidemiology
AKI after cardiac surgery is common, occurring in 20-40% of patients, with 2-6% requiring RRT. It is independently associated with increased short- and long-term mortality, prolonged ICU and hospital stay, and progression to CKD.4 5
2.2 Risk Factors
| Category | Specific Risk Factors |
|---|---|
| Patient-related | Age > 70; pre-existing CKD (eGFR < 60); diabetes mellitus; heart failure (LVEF < 35%); peripheral vascular disease; COPD; anemia (Hgb < 12 g/dL) |
| Procedure-related | Emergency surgery; combined CABG + valve; re-do sternotomy; prolonged cardiopulmonary bypass (CPB) time (> 120 min); aortic cross-clamp time > 60 min; deep hypothermic circulatory arrest |
| Intraoperative | Hypotension (MAP < 55 mmHg for > 10 min on CPB); hemodilution (nadir Hct < 21% on CPB); transfusion of > 2 units pRBC; high-dose vasopressors |
| Postoperative | Low cardiac output syndrome; re-exploration for bleeding; intra-aortic balloon pump; ECMO; nephrotoxin exposure |
2.3 Risk Scores
The Cleveland Clinic Score and the STS (Society of Thoracic Surgeons) score are widely used to predict CSA-AKI risk preoperatively.4
2.4 Prevention Strategies Specific to Cardiac Surgery
| Strategy | Evidence |
|---|---|
| Goal-directed perfusion on CPB | Target MAP ≥ 65-70 mmHg on CPB; maintain Hct > 21-25%; target CI > 2.0 L/min/m² |
| Minimize CPB time | Strong association between CPB duration and AKI risk |
| Biomarker-guided care bundle | The PrevAKI trial demonstrated that a care bundle (optimization of volume status and hemodynamics, avoidance of nephrotoxins, discontinuation of ACEi/ARB, avoidance of hyperglycemia, close monitoring) triggered by elevated TIMP-2•IGFBP7 (> 0.3) reduced AKI incidence from 71.7% to 55.1% (ARR 16.6%, p = 0.004)3 |
| Avoid contrast within 72 hours pre-operatively | Allows renal recovery from any contrast-related insult before CPB |
| Remote ischemic preconditioning (RIPC) | Conflicting evidence; ERICCA trial (n = 1,612) showed no benefit; some smaller studies showed benefit; not recommended as standard |
| Fenoldopam, dopamine, mannitol, natriuretic peptides | Not recommended — no consistent evidence of benefit in preventing CSA-AKI |
3. Contrast-Associated AKI (CA-AKI)
3.1 Updated Understanding
As discussed in Part 2, the risk of contrast-associated AKI has been substantially re-evaluated. The key points for clinical practice:6 7
| Factor | Current Evidence |
|---|---|
| True attributable risk | Clinically significant primarily with intra-arterial contrast in patients with eGFR < 30 mL/min/1.73 m² |
| IV contrast (CT scan) | True attributable risk is very low, even in moderate CKD (eGFR 30-44) |
| NAC (N-acetylcysteine) | No benefit in the PRESERVE trial (n = 5,177); should not be used8 |
| Sodium bicarbonate hydration | No benefit over normal saline in the PRESERVE trial; normal saline is adequate |
| Statins for prevention | Conflicting evidence; not recommended as a specific CA-AKI prevention strategy |
3.2 Prevention Protocol for High-Risk Patients (eGFR < 30)
| Step | Details |
|---|---|
| 1. Pre-hydration | Isotonic saline (0.9% NaCl) at 1-1.5 mL/kg/hr for 6-12 hours before procedure |
| 2. Minimize contrast volume | Target < 3 mL/kg of contrast divided by eGFR (Cigarroa formula); use biplane imaging, LV gram alternatives, and staged procedures |
| 3. Use iso-osmolar or low-osmolar contrast | Iodixanol (iso-osmolar) or iopamidol/iohexol (low-osmolar); avoid high-osmolar contrast |
| 4. Hold nephrotoxins | Discontinue NSAIDs, ACEi/ARB on day of procedure; hold metformin for 48 hours post-procedure |
| 5. Post-hydration | Continue isotonic saline at 1-1.5 mL/kg/hr for 6-12 hours post-procedure |
| 6. Monitor | Serum creatinine at 48-72 hours post-procedure |
Critical Reminder: Do NOT delay emergent diagnostic imaging (CT angiography for PE, aortic dissection, stroke, mesenteric ischemia) due to concern for CA-AKI. The risk of delayed diagnosis far exceeds the risk of contrast-related kidney injury. Hydrate concurrently.
4. Hepatorenal Syndrome (HRS)
4.1 Definition and Classification
Hepatorenal syndrome is a form of functional renal failure occurring in patients with advanced liver disease (decompensated cirrhosis or acute liver failure), characterized by intense renal vasoconstriction in the absence of structural kidney disease.9 10
The nomenclature has been revised by the International Club of Ascites (ICA) in 2015 and further refined:
| Type | Revised Name | Features |
|---|---|---|
| HRS-AKI (formerly HRS type 1) | Hepatorenal syndrome — acute kidney injury | Rapid decline in renal function meeting AKI criteria; typically precipitated by infection (especially SBP), GI bleeding, large-volume paracentesis without albumin, or excessive diuresis; progressive oliguria; median survival 2-4 weeks without treatment |
| HRS-CKD (formerly HRS type 2) | Hepatorenal syndrome — chronic kidney disease | Gradual, steady decline in renal function; eGFR < 60 for > 3 months; often associated with refractory ascites; better prognosis than HRS-AKI |
4.2 Diagnostic Criteria for HRS-AKI
| Criterion | Details |
|---|---|
| Cirrhosis with ascites (or acute liver failure) | Required |
| AKI criteria met | SCr increase ≥ 0.3 mg/dL within 48 hours or ≥ 50% from baseline within 7 days |
| No improvement after 2 days of diuretic withdrawal and albumin expansion (1 g/kg/day, max 100 g/day for 2 days) | Rules out pre-renal AKI responsive to volume |
| Absence of shock | Current or recent shock excluded |
| No nephrotoxin exposure | NSAIDs, aminoglycosides, contrast excluded |
| No structural kidney disease | No proteinuria > 500 mg/day, no hematuria, normal renal ultrasound |
4.3 Treatment
First-Line: Vasoconstrictor Therapy + Albumin
| Agent | Dose | Monitoring | Evidence |
|---|---|---|---|
| Terlipressin | 1 mg IV q4-6h (or continuous infusion 2-4 mg/day); titrate up to 2 mg IV q4-6h if SCr does not decrease by ≥ 25% at day 3; maximum 12 mg/day | Monitor for ischemic complications (intestinal, cardiac, peripheral); contraindicated in coronary artery disease, peripheral vascular disease | CONFIRM trial: terlipressin + albumin showed HRS reversal in 32% vs. 17% placebo (p = 0.006); FDA approved 2022; however, FDA label includes boxed warning for serious respiratory events10 |
| Norepinephrine (alternative if terlipressin unavailable) | 0.5-3 mcg/min, titrate to increase MAP by 10 mmHg | Requires ICU monitoring; central venous access | Non-inferior to terlipressin in some studies; more widely available |
| Midodrine + Octreotide (alternative, lower efficacy) | Midodrine 7.5-15 mg PO TID + Octreotide 100-200 mcg SC TID | Can be used on general ward | Lower response rate than terlipressin or norepinephrine; consider when ICU-level monitoring unavailable |
| Albumin (adjunct to all vasoconstrictors) | 20-40 g/day IV (1 g/kg on day 1, max 100 g; then 20-40 g/day) | Monitor for pulmonary edema (volume overload) | Albumin improves effective circulating volume and enhances vasoconstrictor response |
Second-Line / Bridge to Transplant
| Intervention | Details |
|---|---|
| Renal replacement therapy | Used as a bridge to liver transplant in patients who fail vasoconstrictor therapy; no survival benefit without transplant; CRRT preferred for hemodynamic instability |
| Liver transplant | Definitive treatment for HRS; renal function typically recovers after liver transplant if duration of HRS is < 4-8 weeks; combined liver-kidney transplant considered if HRS has persisted > 4-8 weeks or if duration of RRT exceeds 6-8 weeks |
| TIPS (transjugular intrahepatic portosystemic shunt) | Reduces portal hypertension → improves renal perfusion; evidence limited to observational studies and small RCTs; consider if transplant candidacy is uncertain |
5. Rhabdomyolysis-Induced AKI
5.1 Pathophysiology
Rhabdomyolysis causes AKI through three mechanisms:11
- Tubular obstruction: Myoglobin precipitates in renal tubules, forming casts that obstruct flow (especially in acidic urine)
- Direct tubular toxicity: Ferryl myoglobin generates free radicals and lipid peroxidation products that injure tubular cells
- Renal vasoconstriction: Myoglobin scavenges nitric oxide → intrarenal vasoconstriction and reduced GFR
5.2 CK Thresholds and AKI Risk
| CK Level | AKI Risk | Recommendation |
|---|---|---|
| < 5,000 U/L | Low (< 5%) | Monitor; oral hydration if able |
| 5,000-15,000 U/L | Moderate (10-25%) | IV fluid resuscitation; monitor renal function q6-12h |
| 15,000-40,000 U/L | High (25-50%) | Aggressive IV fluid resuscitation; ICU monitoring; anticipate AKI |
| > 40,000 U/L | Very high (> 50%) | Aggressive IV fluid resuscitation; ICU; prepare for possible RRT |
Note: AKI risk depends not only on CK level but also on concurrent risk factors: volume depletion, acidosis, sepsis, concurrent nephrotoxins, and comorbidities. Some patients develop AKI at CK levels below 15,000 U/L, while others tolerate CK > 100,000 U/L without renal complications.
5.3 Management Protocol
| Intervention | Details |
|---|---|
| Aggressive IV fluid resuscitation | Isotonic saline or Ringer’s lactate at 200-1,000 mL/hr initially; target urine output 200-300 mL/hr (substantially higher than standard oliguria treatment); goal total intake 6-12 L/day in the acute phase; use clinical judgment and monitoring to avoid overresuscitation in patients with cardiac or pulmonary comorbidities |
| Urine alkalinization (controversial) | Sodium bicarbonate added to IV fluids (150 mEq NaHCO3 in 1 L D5W) to target urine pH > 6.5; rationale: alkaline urine reduces myoglobin cast formation and ferryl myoglobin toxicity; evidence is limited to observational studies; avoid if metabolic alkalosis or hypocalcemia develops |
| Avoid mannitol (controversial) | Historically used as an osmotic diuretic; limited evidence of benefit; risk of hyperosmolality and volume depletion; generally not recommended as routine |
| Monitor compartment pressures | Compartment syndrome may be both a cause and consequence of rhabdomyolysis; fasciotomy if compartment pressure > 30 mmHg or within 30 mmHg of diastolic blood pressure |
| Correct electrolyte abnormalities | Hyperkalemia (potassium released from damaged muscle — can be life-threatening within hours); hyperphosphatemia; hypocalcemia (do NOT correct unless symptomatic — calcium may precipitate in damaged muscle); hyperuricemia |
| RRT | Indicated if standard AKI criteria for RRT are met; CRRT preferred for hemodynamic instability; high-flux membranes may clear some myoglobin (MW ~17,800 Da) |
6. Tumor Lysis Syndrome (TLS)
6.1 Definition
Tumor lysis syndrome results from the rapid release of intracellular contents following cytotoxic therapy (or spontaneously) in patients with high-tumor-burden malignancies. It is characterized by hyperuricemia, hyperkalemia, hyperphosphatemia, and hypocalcemia, and can cause AKI through uric acid crystal deposition, calcium phosphate precipitation, and direct tubular injury.12
6.2 Laboratory and Clinical TLS — Cairo-Bishop Criteria
Laboratory TLS: ≥ 2 of the following within 3 days before or 7 days after initiation of cytotoxic therapy:
| Parameter | Threshold |
|---|---|
| Uric acid | ≥ 8.0 mg/dL or 25% increase from baseline |
| Potassium | ≥ 6.0 mEq/L or 25% increase from baseline |
| Phosphorus | ≥ 4.5 mg/dL (adults) or 25% increase from baseline |
| Calcium | ≤ 7.0 mg/dL or 25% decrease from baseline |
Clinical TLS: Laboratory TLS + ≥ 1 of: SCr ≥ 1.5x ULN, cardiac arrhythmia, seizure, or death
6.3 Risk Stratification
| Risk | Tumor Type / Clinical Setting |
|---|---|
| High risk | Burkitt lymphoma/leukemia; ALL with WBC > 100,000/microL; DLBCL with bulky disease; AML with WBC > 100,000; any malignancy with baseline LDH > 2x ULN, uric acid > 8, or pre-existing renal impairment |
| Intermediate risk | AML with WBC 25,000-100,000; ALL with WBC 50,000-100,000; DLBCL without bulky disease; other high-grade lymphomas |
| Low risk | AML with WBC < 25,000; CLL; indolent lymphomas; most solid tumors |
6.4 Prevention and Treatment
| Intervention | Indication | Dose / Protocol |
|---|---|---|
| Aggressive IV hydration | All intermediate and high-risk patients | Isotonic saline at 2-3 L/m²/day (adults: 150-200 mL/hr); target urine output ≥ 2 mL/kg/hr; begin 24-48 hours before chemotherapy |
| Allopurinol | Intermediate-risk patients (prevention) | 300-800 mg/day PO (or 200-400 mg/m²/day IV, max 800 mg/day); start 2-3 days before chemotherapy; adjust dose in renal impairment; does NOT reduce existing uric acid — only prevents new formation (inhibits xanthine oxidase) |
| Rasburicase | High-risk patients (prevention) AND any patient with established TLS (treatment) | 3-6 mg IV as a single dose (some protocols use 0.2 mg/kg; fixed dosing at 3-6 mg is equally effective and more cost-effective); repeat in 24 hours if uric acid remains elevated; contraindicated in G6PD deficiency (causes hemolytic anemia and methemoglobinemia); acts immediately — enzymatic degradation of uric acid to allantoin (soluble); uric acid levels can drop to < 1 mg/dL within 4 hours |
| Phosphate binders | Hyperphosphatemia | Sevelamer 800-1600 mg TID with meals; aluminum hydroxide (short-term only); avoid calcium-based binders if hypercalcemia risk |
| Potassium management | Hyperkalemia | Standard hyperkalemia protocol (see Part 3); anticipate rapid potassium release; frequent monitoring (q4-6h) |
| Avoid urine alkalinization | In TLS specifically | Unlike rhabdomyolysis, urine alkalinization is contraindicated in TLS because alkaline pH promotes calcium phosphate crystal deposition (which is a major cause of TLS-related AKI) |
| RRT | Refractory hyperkalemia, severe metabolic acidosis, fluid overload, or severe AKI | CRRT preferred for continuous potassium and phosphate removal; effective for uric acid clearance though rasburicase is faster and preferred first-line |
7. AKI in Pregnancy
7.1 Epidemiology
Pregnancy-related AKI has become uncommon in high-income countries (incidence ~1-2 per 10,000 pregnancies) but remains a significant cause of maternal morbidity and mortality globally. It tends to cluster in two periods: the first trimester (septic abortion, hyperemesis gravidarum) and the third trimester/peripartum period (pre-eclampsia, HELLP, acute fatty liver of pregnancy, postpartum hemorrhage).13
7.2 Causes by Trimester
| Timing | Common Causes |
|---|---|
| First trimester | Hyperemesis gravidarum (pre-renal); septic abortion; renal cortical necrosis (rare, associated with hemorrhage) |
| Second/Third trimester | Pre-eclampsia/eclampsia; HELLP syndrome (hemolysis, elevated liver enzymes, low platelets); thrombotic microangiopathy (TTP/aHUS); acute fatty liver of pregnancy; bilateral ureteral obstruction (gravid uterus — rare); amniotic fluid embolism |
| Peripartum/Postpartum | Postpartum hemorrhage → ATN; puerperal sepsis; postpartum TTP/aHUS (may present up to 12 weeks postpartum) |
7.3 Key Management Considerations
- Delivery is the definitive treatment for pre-eclampsia, HELLP, and acute fatty liver of pregnancy
- RRT may be required as a bridge (CRRT for hemodynamic instability)
- Complement-mediated TMA (atypical HUS) may be triggered by pregnancy; should be considered when TMA features persist > 3-5 days postpartum despite delivery; eculizumab may be indicated
- Renal biopsy should be considered if the cause of AKI is unclear and treatment would change; biopsy is generally safe in pregnancy up to 28-30 weeks
8. Long-Term Outcomes and Follow-Up
8.1 AKI to CKD Transition
The relationship between AKI and CKD is bidirectional — AKI is a risk factor for CKD, and CKD is a risk factor for AKI. Key evidence:14 15
| Finding | Evidence |
|---|---|
| AKI → new CKD | 25-30% of AKI survivors develop new or worsening CKD within 1-3 years |
| AKI → ESKD | 3-10-fold increased risk of ESKD after AKI requiring RRT (depending on severity and pre-existing kidney function) |
| Dose-response | Risk increases with AKI severity (stage) and number of AKI episodes |
| Even “recovered” AKI | Patients whose SCr returns to baseline still have elevated long-term risk compared to matched patients without AKI |
| Mechanisms | Maladaptive repair, tubular atrophy, interstitial fibrosis, rarefaction of peritubular capillaries, G2/M cell cycle arrest, persistent inflammation |
8.2 Post-Discharge Follow-Up Recommendations
All patients surviving an episode of AKI — particularly Stage 2-3 or AKI requiring RRT — should have structured follow-up:1 16
| Timeframe | Recommended Assessment |
|---|---|
| Within 3 months of discharge | Serum creatinine, eGFR, urinalysis (proteinuria screening), blood pressure measurement; nephrology referral if eGFR < 60 or proteinuria present |
| 6-12 months | Repeat renal function assessment; monitor for CKD progression; medication reconciliation (reinstitution of ACEi/ARB if indicated for renoprotection in CKD) |
| Annually thereafter | eGFR, urinalysis, blood pressure monitoring; ongoing nephrology follow-up if CKD established |
| Patient education | AKI survivors should be informed of their increased risk of CKD; counseled to avoid nephrotoxins (NSAIDs); ensure adequate hydration; report any new episodes of oliguria, edema, or symptoms suggestive of renal dysfunction |
8.3 Nephrology Referral Criteria After AKI
| Indication | Rationale |
|---|---|
| AKI Stage 3 or AKI requiring RRT | High risk of CKD and ESKD; structured monitoring and early intervention can slow progression |
| Incomplete renal recovery (SCr not returned to baseline by discharge) | Requires longitudinal monitoring and may need CKD-specific therapies |
| New proteinuria (UACR > 30 mg/g or UPCR > 150 mg/g) persisting after AKI | Proteinuria is both a marker of kidney damage and a risk factor for CKD progression; may benefit from ACEi/ARB therapy |
| eGFR < 60 mL/min/1.73 m² post-AKI | Meets criteria for CKD and warrants nephrology involvement |
| Recurrent AKI episodes | Each episode increases cumulative risk of CKD and ESKD |
| Need for ongoing RRT at discharge | Dialysis care coordination; access planning; transplant evaluation |
9. Quality Metrics and Performance Improvement
9.1 AKI Recognition and Documentation
Timely recognition of AKI is a prerequisite for appropriate management. Electronic health record-based AKI alert systems have been shown to improve recognition and may facilitate earlier intervention:17
| Quality Metric | Target | Measurement |
|---|---|---|
| AKI recognition rate | > 90% of AKI episodes identified and documented within 24 hours of meeting criteria | Automated electronic surveillance comparing lab values to AKI criteria |
| AKI alert acknowledgment | > 80% of electronic AKI alerts acknowledged and acted upon within 4 hours | EHR alert tracking |
| Nephrotoxin exposure documentation | 100% of AKI patients have nephrotoxin exposure assessed and documented | Pharmacy-triggered review; nephrotoxin stewardship program |
9.2 Nephrotoxin Stewardship
Structured nephrotoxin stewardship programs — analogous to antimicrobial stewardship — have been demonstrated to reduce AKI incidence in hospitalized patients. Key components include:18
| Component | Details |
|---|---|
| Automated nephrotoxin exposure alerts | Electronic alerts triggered when a patient with AKI or at risk for AKI is prescribed a known nephrotoxin |
| Daily nephrotoxin review | Pharmacist-led review of all medications in AKI patients; recommendation for discontinuation or dose adjustment |
| Protocolized aminoglycoside monitoring | Mandatory therapeutic drug monitoring; automatic stop-dates; extended-interval dosing as default |
| Vancomycin stewardship | AUC-guided dosing; avoidance of concurrent piperacillin-tazobactam when possible; monitoring for vancomycin-associated AKI |
| NSAID avoidance | Institutional protocols to limit NSAID use in patients with AKI risk factors |
9.3 RRT Quality Metrics
| Metric | Target | Rationale |
|---|---|---|
| Delivered CRRT dose | ≥ 20 mL/kg/hr effluent (measured, not just prescribed) | Ensuring adequate delivered dose (accounting for downtime) |
| CRRT downtime | < 15% of prescribed therapy time | Minimizing interruptions for filter changes, imaging, procedures |
| Filter life | > 24 hours (median) with citrate anticoagulation | Reflects quality of anticoagulation protocol and circuit management |
| RRT catheter-related BSI rate | < 2 per 1,000 catheter-days | Infection prevention |
| Electrolyte monitoring frequency | Ionized calcium q4-6h on citrate; phosphorus, potassium, magnesium q6-8h on CRRT | Preventing serious electrolyte derangements |
9.4 Bundle-Based Approach to AKI Prevention
Several institutions have implemented “AKI care bundles” based on the principles from the international nephrology guideline organization’s recommendations, demonstrating improved outcomes when applied consistently:16 19
KDIGO-based AKI Care Bundle:
| Component | Action |
|---|---|
| Volume optimization | Assess volume status; avoid hypovolemia and hypervolemia; target euvolemia |
| Blood pressure optimization | Ensure MAP ≥ 65 mmHg; consider higher targets in chronic hypertension |
| Nephrotoxin avoidance | Discontinue all non-essential nephrotoxins; review medication list daily |
| Glycemic control | Target glucose 110-180 mg/dL; avoid hypoglycemia |
| Contrast management | Avoid unnecessary contrast; pre-hydrate if contrast needed in at-risk patients |
| Hemodynamic monitoring | Functional hemodynamic assessment; goal-directed therapy in high-risk settings |
10. Emerging Therapies and Future Directions
10.1 Therapies Under Investigation
| Therapy | Mechanism | Status |
|---|---|---|
| Recombinant alkaline phosphatase | Dephosphorylates inflammatory mediators (LPS, ATP) → reduces inflammation in SA-AKI | Phase III trials in SA-AKI (REVIVAL trial); promising Phase II results |
| Cell-cycle arrest biomarker-guided care bundles | Early identification of at-risk patients → targeted nephroprotective measures before functional decline | PrevAKI-2 trial; concept proven in PrevAKI-1 |
| MSC (mesenchymal stem cell) therapy | Anti-inflammatory, immunomodulatory, and pro-regenerative effects | Early-phase clinical trials; safety established; efficacy uncertain |
| Precision AKI phenotyping | Subphenotyping AKI by biomarker profiles, clinical trajectory, and molecular mechanisms to guide targeted therapy | Active research area; ADQI consensus statements supporting implementation |
| Artificial intelligence-based AKI prediction | Machine learning algorithms applied to EHR data for early AKI detection and risk stratification | Multiple validated models; implementation studies ongoing |
References
Bellomo R, Kellum JA, Ronco C, et al. “Acute Kidney Injury in Sepsis.” Intensive Care Med. 2017;43(6):816-828. DOI: 10.1007/s00134-017-4755-7 ↩︎ ↩︎ ↩︎
Peerapornratana S, Manrique-Caballero CL, Gomez H, et al. “Acute Kidney Injury from Sepsis: Current Concepts, Epidemiology, Pathophysiology, Prevention and Treatment.” Kidney Int. 2019;96(5):1083-1099. DOI: 10.1016/j.kint.2019.05.026 ↩︎ ↩︎
Meersch M, Schmidt C, Hoffmeier A, et al. “Prevention of Cardiac Surgery-Associated AKI by Implementing the KDIGO Guidelines in High Risk Patients Identified by Biomarkers: The PrevAKI Randomized Controlled Trial.” Intensive Care Med. 2017;43(11):1551-1561. DOI: 10.1007/s00134-016-4670-3 ↩︎ ↩︎
O’Neal JB, Shaw AD, Billings FT. “Acute Kidney Injury Following Cardiac Surgery: Current Understanding and Future Directions.” Crit Care. 2016;20(1):187. DOI: 10.1186/s13054-016-1352-z ↩︎ ↩︎
Mehta RH, Grab JD, O’Brien SM, et al. “Bedside Tool for Predicting the Risk of Postoperative Dialysis in Patients Undergoing Cardiac Surgery.” Circulation. 2006;114(21):2208-2216. DOI: 10.1161/CIRCULATIONAHA.106.635573 ↩︎
McDonald JS, McDonald RJ, Comin J, et al. “Frequency of Acute Kidney Injury Following Intravenous Contrast Medium Administration: A Systematic Review and Meta-Analysis.” Radiology. 2013;267(1):119-128. DOI: 10.1148/radiol.12121460 ↩︎
Davenport MS, Perazella MA, Yee J, et al. “Use of Intravenous Iodinated Contrast Media in Patients with Kidney Disease: Consensus Statements from the American College of Radiology and the National Kidney Foundation.” Radiology. 2020;294(3):660-668. DOI: 10.1148/radiol.2019192094 ↩︎
Weisbord SD, Gallagher M, Jneid H, et al. “Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine (PRESERVE).” N Engl J Med. 2018;378(7):603-614. DOI: 10.1056/NEJMoa1710933 ↩︎
Angeli P, Garcia-Tsao G, Nadim MK, et al. “News in Pathophysiology, Definition and Classification of Hepatorenal Syndrome: A Step Beyond the International Club of Ascites (ICA) Consensus Document.” J Hepatol. 2019;71(4):811-822. DOI: 10.1016/j.jhep.2019.07.002 ↩︎
Wong F, Pappas SC, Curry MP, et al. “Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome (CONFIRM).” N Engl J Med. 2021;384(9):818-828. DOI: 10.1056/NEJMoa2008290 ↩︎ ↩︎
Bosch X, Poch E, Grau JM. “Rhabdomyolysis and Acute Kidney Injury.” N Engl J Med. 2009;361(1):62-72. DOI: 10.1056/NEJMra0801327 ↩︎
Howard SC, Jones DP, Pui CH. “The Tumor Lysis Syndrome.” N Engl J Med. 2011;364(19):1844-1854. DOI: 10.1056/NEJMra0904569 ↩︎
Fakhouri F, Vercel C, Frémeaux-Bacchi V. “Obstetric Nephrology: AKI and Thrombotic Microangiopathies in Pregnancy.” Clin J Am Soc Nephrol. 2012;7(12):2100-2106. DOI: 10.2215/CJN.13121211 ↩︎
Chawla LS, Eggers PW, Star RA, et al. “Acute Kidney Injury and Chronic Kidney Disease as Interconnected Syndromes.” N Engl J Med. 2014;371(1):58-66. DOI: 10.1056/NEJMra1214243 ↩︎
See EJ, Jayasinghe K, Glassford N, et al. “Long-term Risk of Adverse Outcomes After Acute Kidney Injury: A Systematic Review and Meta-analysis of Cohort Studies Using Consensus Definitions of Exposure.” Kidney Int. 2019;95(1):160-172. DOI: 10.1016/j.kint.2018.08.036 ↩︎
Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. “KDIGO Clinical Practice Guideline for Acute Kidney Injury.” Kidney Int Suppl. 2012;2(1):1-138. DOI: 10.1038/kisup.2012.1 ↩︎ ↩︎
Wilson FP, Shashaty M, Testani J, et al. “Automated, Electronic Alerts for Acute Kidney Injury: A Single-Blind, Parallel-Group, Randomised Controlled Trial.” Lancet. 2015;385(9981):1966-1974. DOI: 10.1016/S0140-6736(15)60266-5 ↩︎
Goldstein SL, Mottes T, Simpson K, et al. “A Sustained Quality Improvement Program Reduces Nephrotoxic Medication-Associated Acute Kidney Injury.” Kidney Int. 2016;90(1):212-221. DOI: 10.1016/j.kint.2016.03.031 ↩︎
Ostermann M, Zarbock A, Goldstein S, et al. “Recommendations on Acute Kidney Injury Biomarkers from the Acute Disease Quality Initiative Consensus Conference: A Consensus Statement.” JAMA Netw Open. 2020;3(10):e2019209. DOI: 10.1001/jamanetworkopen.2020.19209 ↩︎